NYMX vs. ICCC, TRIB, AWH, OCX, BMRA, CDIO, MYMD, TKNO, ACHV, and HEPA
Should you be buying Nymox Pharmaceutical stock or one of its competitors? The main competitors of Nymox Pharmaceutical include ImmuCell (ICCC), Trinity Biotech (TRIB), Aspira Women's Health (AWH), OncoCyte (OCX), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector.
Nymox Pharmaceutical vs.
Nymox Pharmaceutical (NASDAQ:NYMX) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
Nymox Pharmaceutical received 29 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 51.72% of users gave Nymox Pharmaceutical an outperform vote.
Nymox Pharmaceutical has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
In the previous week, Nymox Pharmaceutical had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Nymox Pharmaceutical and 0 mentions for ImmuCell. Nymox Pharmaceutical's average media sentiment score of 0.00 equaled ImmuCell's average media sentiment score.
ImmuCell has higher revenue and earnings than Nymox Pharmaceutical. Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
0.8% of Nymox Pharmaceutical shares are held by institutional investors. Comparatively, 12.6% of ImmuCell shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by company insiders. Comparatively, 6.3% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Nymox Pharmaceutical has a net margin of 0.00% compared to ImmuCell's net margin of -33.23%. ImmuCell's return on equity of -17.30% beat Nymox Pharmaceutical's return on equity.
Summary
ImmuCell beats Nymox Pharmaceutical on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NYMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nymox Pharmaceutical Competitors List
Related Companies and Tools
